– Late-breaking oral presentation to highlight efficacy and safety of ESK-001 in a Phase 2 clinical trial and open label extension (OLE) study in adults with moderate-to-severe plaque psoriasis (STRIDE) – – Additional Phase 1 poster presentation to describe pharmacokinetic and pharmacodynamic characteristics of ESK-001 in healthy participants – – The Company will host a virtual investor event following the Phase 2 data presentation – SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Alumis Inc., a clinical stage biopharmaceutical company developing oral therapies using a precision approach to transform the lives of patients with immune-mediated diseases, today announced two clinical data presentations at the American Academy of Dermatology Annual Meeting taking place March 8-12, 2024, in San Diego, CA.

–在中重度斑块状银屑病（STRIDE）成人的2期临床试验和开放标签延伸（OLE）研究中，迟发性口腔介绍突出了ESK-001的有效性和安全性––描述ESK-001在健康参与者中的药代动力学和药效学特征的附加第一阶段海报演示–公司将在第二阶段数据演示后举办虚拟投资者活动–加利福尼亚州南旧金山，2024年3月4日（环球新闻通讯）-Alumis Inc。，一家临床阶段的生物制药公司使用精确的方法开发口服疗法，以改变免疫介导疾病患者的生活，今天在2024年3月8日至12日于加利福尼亚州圣地亚哥举行的美国皮肤病学会年会上宣布了两份临床数据报告。

Details regarding the presentations are as follows: Oral PresentationTitle: Efficacy and Safety of ESK-001, a Highly Selective Oral TYK2 Inhibitor, in a Phase 2 Study inAdults with Moderate-to-severe Plaque Psoriasis (STRIDE)Session Title: S026 – Late-Breaking Research: Session 1Location: Room 20BDate and Time: March 9, 10:20–10:30 a.m.

有关演示的详细信息如下：口服演示标题：ESK-001（一种高选择性口服TYK2抑制剂）在中重度斑块状银屑病（STRIDE）第二阶段研究中的疗效和安全性会议标题：S026–晚期研究：会议1地点：20B室日期和时间：3月9日上午10:20–10:30。

PT E-Poster PresentationTitle: Pharmacokinetic and Pharmacodynamic Characteristics of ESK-001, an Oral Allosteric TYK2 Inhibitor, in Phase 1 Healthy Volunteer TrialsPoster number: 53968 Alumis will also host a virtual investor event to review the ESK-001 Phase 2 clinical data being presented at AAD on March 9 at 5:00 p.m.

PT E-Poster PresentationTitle：口服变构TYK2抑制剂ESK-001在第一阶段健康志愿者试验中的药代动力学和药效学特征海报编号：53968 Alumis还将举办虚拟投资者活动，以审查3月9日下午5:00在AAD上提交的ESK-001第二阶段临床数据。

PT. To access the live webcast, please register by visiting the Events page on the Alumis website. About AlumisAlumis is a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize outcomes and transform the lives of patients with immune-mediated diseases.

PT。要访问在线直播，请访问Alumis网站上的活动页面进行注册。关于AlumisAlumis是一家临床阶段的生物制药公司，使用精确的方法开发口服疗法，以优化结果并改变免疫介导疾病患者的生活。

Le.

乐。